Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease
Blood · 2023
DOI: 10.1182/blood.2022017074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Erica M Sparkenbaugh und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Factor XII. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, BLRD VA.
Abstract (Originalsprache)
A hypercoagulable state, chronic inflammation, and increased risk of venous thrombosis and stroke are prominent features in patients with sickle cell disease (SCD). Coagulation factor XII (FXII) triggers activation of the contact system that is known to be involved in both thrombosis and inflammation, but not in physiological hemostasis. Therefore, we investigated whether FXII contributes to the prothrombotic and inflammatory complications associated with SCD. We found that when compared with healthy controls, patients with SCD exhibit increased circulating biomarkers of FXII activation that are associated with increased activation of the contact pathway. We also found that FXII, but not tissue factor, contributes to enhanced thrombin generation and systemic inflammation observed in sickle cell mice challenged with tumor necrosis factor α. In addition, FXII inhibition significantly reduced experimental venous thrombosis, congestion, and microvascular stasis in a mouse model of SCD. Moreover, inhibition of FXII attenuated brain damage and reduced neutrophil adhesion to the brain vasculature of sickle cell mice after ischemia/reperfusion induced by transient middle cerebral artery occlusion. Finally, we found higher FXII, urokinase plasminogen activator receptor, and αMβ2 integrin expression in neutrophils of patients with SCD compared with healthy controls. Our data indicate that targeting FXII effectively reduces experimental thromboinflammation and vascular complications in a mouse model of SCD, suggesting that FXII inhibition may provide a safe approach for interference with inflammation, thrombotic complications, and vaso-occlusion in patients with SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
- Louisiana State University Health Sciences Center, Shreveport, LA.
- Hematology and Oncology Division, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH.
- Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.
- Division of Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL.
- Aronora Inc, Portland, OR.
ORCID-Profile: Erica M Sparkenbaugh, Michael W Henderson, Christina Abrams, Anton Ilich, Fatima Trebak, Nirupama Ramadas, Dillon Bohinc, Michael Wallisch, Thomas Renné, Andras Gruber, David Gailani, Malgorzata Kasztan, Gregory M Vercellotti, Felicity E Gavins, Evi X Stavrou, Nigel S Key, Rafal Pawlinski
Förderung
- NHLBI NIH HHS
- BLRD VA
Zitieren
APA
Sparkenbaugh, E. M., Henderson, M. W., Miller-Awe, M., Abrams, C., Ilich, A., Trebak, F., Ramadas, N., Vital, S., Bohinc, D., Bane, K. L., Chen, C., Patel, M., Wallisch, M., Renné, T., Gruber, A., Cooley, B., Gailani, D., Kasztan, M., Vercellotti, G. M., …, & Pawlinski, R. (2023). Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease. Blood. https://doi.org/10.1182/blood.2022017074
Vancouver
Sparkenbaugh EM, Henderson MW, Miller-Awe M, Abrams C, Ilich A, Trebak F, et al. Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease. Blood. 2023. doi:10.1182/blood.2022017074
BibTeX
@article{Sparkenbaugh2023,
author = {Sparkenbaugh, Erica M and Henderson, Michael W and Miller-Awe, Megan and Abrams, Christina and Ilich, Anton and Trebak, Fatima and Ramadas, Nirupama and Vital, Shantel and Bohinc, Dillon and Bane, Kara L and Chen, Chunsheng and Patel, Margi and Wallisch, Michael and Renné, Thomas and Gruber, Andras and Cooley, Brian and Gailani, David and Kasztan, Malgorzata and Vercellotti, Gregory M and Belcher, John D and Gavins, Felicity E and Stavrou, Evi X and Key, Nigel S and Pawlinski, Rafal},
title = {Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022017074}
}
EUVIMED